The prevailing 4 exams, which examine for the presence of SARS-CoV-2 antibodies developed after both an an infection or a vaccine dose, may additionally inform choices on the necessity for boosters to guard towards the illness, it mentioned in a press release.
The non-exclusive licensing settlement reached with the Spanish Nationwide Analysis Council (CSIC), a public analysis institute providing the know-how as a worldwide public good, is the primary take a look at licence signed by the WHO’s Medicines Patent Pool (MPP).
“The intention of the licence is to facilitate the fast manufacture and commercialisation of CSIC’s COVID-19 serological take a look at worldwide,” the WHO mentioned.
“The licence shall be royalty-free for low- and middle-income international locations and can stay legitimate till the date the final patent expires,” it mentioned.
The exams are easy to make use of and appropriate for even rural settings with a primary laboratory infrastructure, it added.
WHO director-general Tedros Adhanom Ghebreyesus welcomed the deal which he hoped would encourage different builders to share instruments towards COVID-19 which has killed 5.4 million individuals for the reason that virus emerged in central China in December 2019.
“That is the sort of open and clear licence we have to transfer the needle on entry throughout and after the pandemic,” Tedros mentioned.
“I urge builders of COVID-19 vaccines, remedies and diagnostics to observe this instance and switch the tide on the pandemic and on the devastating international inequity this pandemic has spotlighted.”
Medical doctors With out Borders (MSF) welcomed the deal, noting that presently WHO solely had one antibody take a look at utilizing quantitative immunoassays (ELISA) made by Roche Holding AG which may solely be used with the Swiss-based drugmaker’s personal system.
“In an effort to overcome the monopoly of huge diagnostics corporations reminiscent of Roche, and to facilitate manufacturing and provide of dependable ELISA antibody exams in all international locations, the open licence from CSIC to WHO C-TAP (COVID-19 Expertise Entry Pool) is a crucial step ahead,” the activist group mentioned.
“Nonetheless, one licence from one know-how proprietor just isn’t sufficient to open up the complete platform in order that builders in international locations can enhance their exams for COVID-19 antibodies. Eradicating mental property limitations on all key know-how elements, and facilitating open sharing, pooling and transferring of applied sciences, knowledge and know-how, are vital to ensure and enhance entry to COVID-19 diagnostics for all.”